Clearmind Medicine Inc. (Nasdaq, CSE: CMND) (FSE: CWY), a biotech company developing psychedelic-derived therapeutics, has issued the following letter to shareholders from its CEO, Dr. Adi Zuloff-Shani. Dear Fellow Shareholders: Clearmind’s overarching mission since inception has been to promptly bring our proprietary compound CMND-100 to clinical trials while developing additional proprietary psychedelic compounds for next-generation novel drug…